Organic compounds -- part of the class 532-570 series – Organic compounds – Unsubstituted hydrocarbyl chain between the ring and the -c-...
Patent
1996-10-09
2000-08-29
Berch, Mark L.
Organic compounds -- part of the class 532-570 series
Organic compounds
Unsubstituted hydrocarbyl chain between the ring and the -c-...
C07D47720
Patent
active
061110981
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a crystal of pyrrolidylthiocarbapenem derivative excellent in storage stability and solubility, a lyophilized preparation containing the crystal and a process for producing the same.
BACKGROUND ART
(1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamoylaminomethyl-1-pyrr olidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid represented by the following formula (hereinafter referred to as S-4661 in the specification) is a pyrrolidylthiocarbapenem derivative. S-4661 is a useful compound as an antimicrobial drug, and orally or parenterally administered. ##STR2##
S-4661 itself is described in Japanese Laid-Open Patent Publication (Kokai) No. 5-294970. However, no crystal of S-4661 is described in the Publication. When S-4661 is produced, conventionally, a process for producing it in an amorphous form only is known. However, an amorphous solid of S-4661 has insufficient stability during storage. Therefore, when S-4661 is stored under ordinary storage conditions for a long period, the color thereof is changed, and the purity disadvantageously deteriorates. Thus, it is desired to prepare a crystalline preparation of S-4661 having a higher storage stability than an amorphous preparation. In particular, among the crystalline preparations, a preparation containing an inner salt is more preferable in that it is unnecessary to use an additive in a large amount in order to form a salt.
Furthermore, among the crystalline preparations of S-4661, a crystalline lyophilized preparation is preferable, because it is generally easy to ensure sterility of a lyophilized preparation and to remove particulate matters from the lyophilized preparation.
As a general process for producing a lyophilized preparation, a variety of processes are conventionally known. For example, Japanese Laid-Open Patent Publication (Kokai) Nos. 61-172878, 63-174927 and 4-59730 disclose that NaCl is added to a solution before lyophilization in order to improve solubility and stability of an amorphous lyophilized preparation. Japanese Laid-Open Patent Publication (Kokai) No. 4-338332 discloses that Na.sub.2 CO.sub.3 or NaHCO.sub.3 is added to a drug in a form of a hydrochloride salt so that an insoluble free base is not deposited.
The following processes are known as a process for obtaining a crystalline lyophilized preparation: for example, Japanese Patent Publication (Kokoku) No. 4-66202 discloses that an aqueous solution of a drug is allowed to be in a supercooled state without freezing, and crystal nuclei are generated in the supercooled state; Japanese Patent Publication (Kokoku) No. 60-19758 discloses that an aqueous solution of a drug containing 2 to 25 v/v % of alcohol is gradually cooled to freeze water and crystal nuclei are generated in a state of a concentrated alcohol solution; and Japanese Patent Publication (Kokoku) Nos. 60-19759, 03-74643 and Japanese Laid-Open Patent Publication (Kokai) No. 5-271241 disclose that an aqueous solution of a drug is frozen at a predetermined temperature, then warmed to a predetermined temperature, and retained at a constant temperature.
Conditions suitable for lyophilization are varied depending on the drugs to be lyophilized. Therefore, the aforementioned known processes are not necessarily suitable for a process for producing a lyophilized preparation containing the crystal of S-4661. For example, since the process for lyophilization by freezing an aqueous solution containing S-4661 at a predetermined temperature and retaining it at a constant temperature takes a very long time, it is not suitable as an industrial process.
As described above, no process suitable to obtain a crystal of S-4661, in particular, an inner salt crystal, and no lyophilization process suitable to obtain a lyophilized preparation containing the crystal have been found yet.
DISCLOSURE OF THE INVENTION
A crystal of S-4661 of the present invention is a crystal of pyrrolidylthiocarbapenem derivative S-4661 represented by the following formula. ##STR3##
A lyophilized preparat
REFERENCES:
patent: 3697506 (1972-10-01), Butler
patent: 4029655 (1977-06-01), Cise
patent: 4104391 (1978-08-01), Cise
patent: 4146971 (1979-04-01), Bornstein et al.
patent: 4432987 (1984-02-01), Barth et al.
patent: 4748238 (1988-05-01), Shih
patent: 4966899 (1990-10-01), Kohno et al.
patent: 5286856 (1994-02-01), Kaneko et al.
patent: 5424069 (1995-06-01), Kaneko et al.
patent: 5539102 (1996-07-01), Sendo et al.
CRC Handbook, 62nd edition (CRC Press), p. F-101, 1974.
Fujikane Kazuichi
Hamada Yoshinori
Inoue Masayoshi
Matsubara Fumihiko
Oda Katsuo
Berch Mark L.
Brown Karen E.
Haley, Jr. James F.
Shionogi & Co. Ltd.
LandOfFree
Crystal of pyrrolidylthiocarbapenem derivative, lyophilized prep does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystal of pyrrolidylthiocarbapenem derivative, lyophilized prep, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal of pyrrolidylthiocarbapenem derivative, lyophilized prep will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1251345